Explore
Validate
Learn
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA055478 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA055478, RRID:AB_2682830
- Product name
- Anti-HHLA2
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human HHLA2, Gene description: HERV-H LTR-associating 2, Alternative Gene Names: B7H7, Validated applications: WB, IHC, Uniprot ID: Q9UM44, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.1 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy
HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma
HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival
HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma
Li Y, Lv C, Yu Y, Wu B, Zhang Y, Lang Q, Liang Z, Zhong C, Shi Y, Han S, Xu F, Tian Y
Journal of Advanced Research 2023;47
Journal of Advanced Research 2023;47
HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
Huang F, Wu J, Cheng X, Wang J, Wen X, Li J, Zhang Q, Jiang H, Ding Q, Zhu X, Zhang X, Ding Y, Li D
Frontiers in Immunology 2022;13
Frontiers in Immunology 2022;13
HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma
Zhou Q, Li K, Chen X, He H, Peng S, Peng S, Wang Q, Li Z, Tao Y, Cai W, Liu R, Huang H
Journal for ImmunoTherapy of Cancer 2020;8(1):e000157
Journal for ImmunoTherapy of Cancer 2020;8(1):e000157
HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival
Yan H, Qiu W, Koehne de Gonzalez A, Wei J, Tu M, Xi C, Yang Y, Peng Y, Tsai W, Remotti H, Miao Y, Su G
Cancer Letters 2019;442
Cancer Letters 2019;442
HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma
Qi Y, Deng G, Xu P, Zhang H, Yuan F, Geng R, Jiang H, Liu B, Chen Q
Oncology Reports 2019
Oncology Reports 2019
No comments: Submit comment
Supportive validation
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Orthogonal validation
- Main image
- Experimental details
- Immunohistochemistry analysis in human colon and liver tissues using HPA055478 antibody. Corresponding HHLA2 RNA-seq data are presented for the same tissues.
- Sample type
- Human
- Protocol
- Protocol
